Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets.
Drug Des Devel Ther
; 11: 1267-1272, 2017.
Article
em En
| MEDLINE
| ID: mdl-28458520
ABSTRACT
PURPOSE:
Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with the possibility of establishing it as an additional mechanism of anti-glaucomatous action. MATERIALS ANDMETHODS:
The anti-aggregating effects of a series of anti-glaucomatous eye drops were determined on human platelets in the platelet aggregation model, using four known aggregating factors (platelet activating factor [PAF], adenosine diphosphate [ADP], thrombin receptor-activating peptide [TRAP], and arachidonic acid [AA]).RESULTS:
Almost all of the tested samples inhibited platelet aggregation induced by PAF, ADP, TRAP, and AA, except for Alphagan, which did not demonstrate inhibition of ADP- and TRAP-induced aggregation at a wide range of concentrations. Trusopt, Betoptic, and Azarga eye drops were the most potent inhibitors of all four aggregating factors, while Alphagan was the least potent (P<0.05).CONCLUSION:
This study shows that anti-glaucomatous eye drops possess anti-platelet effects, and this was shown for the first time by experimenting on human platelets.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Soluções Oftálmicas
/
Fator de Ativação de Plaquetas
/
Difosfato de Adenosina
/
Glaucoma
/
Ácido Araquidônico
/
Complexo Mediador
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article